SG10201703677VA - Methods of treating s. aureus-associated diseases - Google Patents

Methods of treating s. aureus-associated diseases

Info

Publication number
SG10201703677VA
SG10201703677VA SG10201703677VA SG10201703677VA SG10201703677VA SG 10201703677V A SG10201703677V A SG 10201703677VA SG 10201703677V A SG10201703677V A SG 10201703677VA SG 10201703677V A SG10201703677V A SG 10201703677VA SG 10201703677V A SG10201703677V A SG 10201703677VA
Authority
SG
Singapore
Prior art keywords
aureus
treating
methods
associated diseases
diseases
Prior art date
Application number
SG10201703677VA
Other languages
English (en)
Inventor
Bret Sellman
Christine Tkaczyk
Melissa Hamilton
Lei Hua
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG10201703677VA publication Critical patent/SG10201703677VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201703677VA 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases SG10201703677VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06

Publications (1)

Publication Number Publication Date
SG10201703677VA true SG10201703677VA (en) 2017-06-29

Family

ID=50685101

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201703677VA SG10201703677VA (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases
SG11201503231YA SG11201503231YA (en) 2012-11-06 2013-11-05 METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201503231YA SG11201503231YA (en) 2012-11-06 2013-11-05 METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES

Country Status (13)

Country Link
US (3) US9845348B2 (enrdf_load_stackoverflow)
EP (1) EP2928490B1 (enrdf_load_stackoverflow)
JP (2) JP6506172B2 (enrdf_load_stackoverflow)
KR (3) KR20210083389A (enrdf_load_stackoverflow)
CN (2) CN112316135A (enrdf_load_stackoverflow)
AU (2) AU2013341421A1 (enrdf_load_stackoverflow)
BR (1) BR112015010126B1 (enrdf_load_stackoverflow)
CA (1) CA2890385C (enrdf_load_stackoverflow)
ES (1) ES2912267T3 (enrdf_load_stackoverflow)
MX (1) MX367082B (enrdf_load_stackoverflow)
RU (1) RU2661406C2 (enrdf_load_stackoverflow)
SG (2) SG10201703677VA (enrdf_load_stackoverflow)
WO (1) WO2014074470A1 (enrdf_load_stackoverflow)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2718320T (lt) 2011-06-10 2018-04-10 Medimmune Limited Anti-pseodomonas psl surišančios molekulės ir jų panaudojimas
SI2776065T1 (sl) 2011-11-07 2020-10-30 Medimmune Limited Kombinacijske terapije z uporabo molekul, ki vežejo anti-Pseudomonas Psl in PcrV
KR20210083389A (ko) * 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
CA2890427C (en) * 2012-11-06 2022-05-31 Medimmune, Llc Antibodies to s. aureus surface determinants
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
TW202019956A (zh) 2018-07-24 2020-06-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
KR20210072057A (ko) 2018-10-09 2021-06-16 메디뮨 엘엘씨 항-황색포도상구균 항체의 조합
MX2021004114A (es) 2018-10-09 2021-07-16 Medimmune Llc Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
EP3938388A1 (en) 2019-03-13 2022-01-19 MedImmune, LLC Decreasings staphylococcus aureus infections in colonized patients
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080131457A1 (en) 2006-06-12 2008-06-05 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
KR101661946B1 (ko) * 2007-08-31 2016-10-05 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
WO2011008939A2 (en) * 2009-07-16 2011-01-20 Medical College Of Georgia Research Institute, Inc. Porous-wall hollow glass microspheres as carriers for biomolecules
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
WO2012109285A2 (en) * 2011-02-08 2012-08-16 Medimmune, Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
EP2672989A4 (en) * 2011-02-08 2015-03-11 Integrated Biotherapeutics Inc IMMUNOGENIC COMPOSITION WITH ALPHA-HEMOLYSIN OLIGOPEPTIDES
KR20210083389A (ko) * 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
CA2890427C (en) 2012-11-06 2022-05-31 Medimmune, Llc Antibodies to s. aureus surface determinants
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Also Published As

Publication number Publication date
SG11201503231YA (en) 2015-05-28
EP2928490A4 (en) 2016-11-02
US20160257733A1 (en) 2016-09-08
HK1215173A1 (zh) 2016-08-19
KR20210083389A (ko) 2021-07-06
US10759849B2 (en) 2020-09-01
RU2661406C2 (ru) 2018-07-16
US20200109191A1 (en) 2020-04-09
JP6926138B2 (ja) 2021-08-25
US9845348B2 (en) 2017-12-19
BR112015010126A2 (enrdf_load_stackoverflow) 2017-08-22
CA2890385A1 (en) 2014-05-15
JP2015536951A (ja) 2015-12-24
JP2019142888A (ja) 2019-08-29
US10457724B2 (en) 2019-10-29
AU2018236849B2 (en) 2020-05-21
CN104780934A (zh) 2015-07-15
MX2015005481A (es) 2016-01-14
KR20200102533A (ko) 2020-08-31
EP2928490A1 (en) 2015-10-14
WO2014074470A1 (en) 2014-05-15
JP6506172B2 (ja) 2019-04-24
MX367082B (es) 2019-08-05
US20190002540A1 (en) 2019-01-03
BR112015010126B1 (pt) 2022-11-01
KR102272744B1 (ko) 2021-07-06
KR20150092738A (ko) 2015-08-13
AU2013341421A1 (en) 2015-06-04
CN112316135A (zh) 2021-02-05
CA2890385C (en) 2022-07-12
EP2928490B1 (en) 2022-03-30
RU2015121617A (ru) 2016-12-27
AU2018236849A1 (en) 2018-10-18
ES2912267T3 (es) 2022-05-25

Similar Documents

Publication Publication Date Title
DK3292875T3 (en) Compositions and methods for treating diseases
SG10201703677VA (en) Methods of treating s. aureus-associated diseases
GB201506561D0 (en) Treatment of amblyopia
EP2906295A4 (en) METHODS OF TREATING OCULAR DISEASES
GB2497886B (en) Hair treatment methods
IL239273A0 (en) A method of treating diseases
IL238592A0 (en) Methods for treating liver diseases
AP3819A (en) Treatment of wax
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
GB201207907D0 (en) Treatment of depression
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB2500999B (en) Hair treatment methods
EP2911662A4 (en) METHOD OF TREATING A DISEASE
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201204645D0 (en) Treatment of disease
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment
GB201205449D0 (en) Treatment process
GB201212604D0 (en) New treatment